abstract |
The present application provides methods for treating hidradenitis suppurativa by administering a compound that inhibits JAK1 and / or JAK2, or a pharmaceutically acceptable salt thereof, wherein said compound is ruxolitinib; ruxolitinib, where one or more hydrogen atoms are replaced with deuterium atoms; {1- {1- [3-fluoro-2- (trifluoromethyl) isonicotinoyl] piperidin-4-yl} -3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H- pyrazol-1-yl] azetidin-3-yl} acetonitrile; 4- {3- (cyanomethyl) -3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl] azetidin-1-yl} -N- [ 4-fluoro-2- (trifluoromethyl) phenyl] piperidine-1-carboxamide; [3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl] -1- (1 - {[2- (trifluoromethyl) pyrimidin-4-yl ] carbonyl} piperidin-4-yl) azetidin-3-yl] acetonitrile; 4- [3- (cyanomethyl) -3- (3 ', 5'-dimethyl-1H, 1'H-4,4'-bipyrazol-1-yl) azetidin-1-yl] -2,5-difluoro- N - [(1S) -2,2,2-trifluoro-1-methylethyl] benzamide; among others. |